Value Pickings
Long/short equity, deep value, long-term horizon

Infinity Pharmaceuticals Presents A Compelling Risk Reward Ahead Of Imminent Catalysts

Infinity Pharmaceuticals (NASDAQ:INFI) is a drug discovery and development company based in Cambridge, MA.

The company's lead product is IPI-145, being developed for both Hematologic malignancies and Inflammation. Investor's focus is firmly on IPI-145 and its potential in various types of blood cancer (CLL, iNHL, MCL, T-Cell). IPI-145 is a potent, oral inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K).

What are PI3Ks?

PI3Ks are a family of enzymes involved in key immune cell functions. The PI3K-delta and PI3K-gamma isoforms are preferentially expressed in leukocytes (white blood cells), where they have distinct and non-overlapping roles in key cellular functions, including cell proliferation, cell differentiation, cell migration and immunity. Therefore, inhibition of PI3K-delta and PI3K-gamma may have...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details